Similarly, the KEYNOTE-091 trial of 1177 patients with resected stage IB-IIIA NSCLC showed improved DFS compared to placebo, regardless of PD-L1 status [175]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.